2 results
Approved WMORecruiting
Phase 1: • To determine the MTD/RP2D regimen of brigatinib monotherapy when administered in pediatric and AYA patients with ALK+ ALCL or ALK+ solid tumors, including ALK+ IMT.• To characterize the PK of brigatinib administered as monotherapy in…
Approved WMORecruiting
The primary objective is to determine the diagnostic accuracy of the automated diagnostic software (mPDia, Heuron) using SMWI to distinguish neurodegenerative parkinsonism from patients with non-neurodegenerative parkinsonism compared with the final…